Flputnam Investment Management Co. Sells 630 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Flputnam Investment Management Co. cut its position in IQVIA Holdings Inc. (NYSE:IQV) by 17.3% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 3,013 shares of the medical research company’s stock after selling 630 shares during the quarter. Flputnam Investment Management Co.’s holdings in IQVIA were worth $592,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in IQV. Capital Performance Advisors LLP bought a new stake in shares of IQVIA during the third quarter worth about $27,000. Avior Wealth Management LLC increased its stake in IQVIA by 117.6% in the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after buying an additional 87 shares during the last quarter. Synergy Asset Management LLC bought a new position in shares of IQVIA during the 4th quarter worth approximately $33,000. Assetmark Inc. boosted its stake in shares of IQVIA by 612.5% in the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after buying an additional 196 shares during the last quarter. Finally, Ashton Thomas Securities LLC bought a new position in shares of IQVIA in the third quarter valued at approximately $57,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on IQV shares. William Blair reissued an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Thursday, November 28th. Truist Financial reissued a “buy” rating and set a $263.00 target price (up from $261.00) on shares of IQVIA in a research report on Monday, February 10th. JPMorgan Chase & Co. lowered their price target on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a report on Tuesday, February 18th. Finally, Stifel Nicolaus reduced their price objective on IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a report on Friday, February 7th. Four research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, IQVIA has a consensus rating of “Moderate Buy” and an average target price of $251.22.

IQVIA Trading Down 2.2 %

Shares of IQV opened at $184.67 on Tuesday. IQVIA Holdings Inc. has a twelve month low of $184.06 and a twelve month high of $261.73. The stock has a market cap of $32.52 billion, a PE ratio of 24.62, a P/E/G ratio of 1.99 and a beta of 1.48. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The business’s 50-day moving average price is $198.84 and its 200-day moving average price is $214.25.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, equities analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.